KYTX
Kyverna Therapeutics Inc
NASDAQ · Biotechnology
$7.93
+0.66 (+9.08%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 77.52M | 81.06M | 62.85M |
| Net Income | -14,424,701 | -12,557,463 | -9,873,224 |
| EPS | — | — | — |
| Profit Margin | -18.6% | -15.5% | -15.7% |
| Rev Growth | +5.4% | +22.1% | -7.0% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 80.87M | 71.42M | 75.37M |
| Total Equity | 329.14M | 353.67M | 302.41M |
| D/E Ratio | 0.25 | 0.20 | 0.25 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -20,391,428 | -20,108,436 | -16,996,352 |
| Free Cash Flow | -5,835,314 | -8,946,067 | -4,753,485 |